# Dapagliflozin in Systemic Right Ventricle (DAPA-SERVE)

> **NCT05717257** · PHASE4 · UNKNOWN · sponsor: **Monaldi Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Dapagliflozin Adverse Reaction
- Efficacy
- Systemic Right Ventricle

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab

## Key facts

- **NCT ID:** NCT05717257
- **Lead sponsor:** Monaldi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-01
- **Primary completion:** 2023-08
- **Final completion:** 2024-08
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05717257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05717257, "Dapagliflozin in Systemic Right Ventricle (DAPA-SERVE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05717257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*